bluebird bio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew Obenshain
- Full Time Employees
- 248
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Jun 19, 2013
- CIK
- 0001293971
- Website
- bluebirdbio.com
- Similar Companies
- Business
- Bluebird bio, Inc., operating within the biotechnology sector, is dedicated to the research, development, and commercialization of potentially curative gene therapies for severe genetic conditions. Its portfolio includes three approved, one-time ex-vivo gene therapies: Zynteglo (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia in adult and pediatric patients; Skysona (elivaldogene autotemcel), approved to slow the progression of neurological dysfunction in boys aged 4-17 with early, active cerebral adrenoleukodystrophy, though the FDA is currently investigating reports of hematologic malignancies associated with this therapy; and Lyfgenia (lovotibeglogene autotemcel), cleared for individuals 12 years and older with sickle cell disease who have a history of vaso-occlusive events, which carries a boxed warning regarding the potential risk for blood cancers. The company emphasizes expanding patient access through a network of qualified treatment centers and conducts long-term follow-up studies to assess the durability and safety of its treatments. In a pivotal development, bluebird bio transitioned to a privately-held entity in June 2025, following its acquisition by investment funds managed by The Carlyle Group and SK Capital Partners. This strategic move aims to infuse significant capital and leadership to accelerate the commercial scaling and availability of its approved gene therapies for beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy. The company was originally founded in 1992 as Genetix Pharmaceuticals, Inc., changing its name to bluebird bio, Inc. in September 2010, and is now headquartered in Somerville, Massachusetts.
FULTON FINANCIAL MERGES ITS BLUE FOUNDRY BANK SUBSIDIARY INTO FULTON BANK, N.A.
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Intermedia Launches Cloud Calling for UNIVERGE BLUE with KDDI, Significantly Expanding Nationwide UCaaS Availability in Japan
ISS and Glass Lewis Support BIMIZCI's Case for Change at Medallion Financial. Both Recommend Stockholders Vote on the BLUE Proxy Card FOR Election of Two BIMIZCI Nominees to Medallion Board
BLUE OWL CAPITAL INC. INVESTOR ALERT: Haeggquist & Eck, LLP Announces Investigation of Blue Owl Capital Inc.'s Directors and Officers for Breach of Fiduciary Duties – OWL
BLUE WATER ACQUISITION CORP. IV ANNOUNCES LETTER OF INTENT FOR A PROPOSED ACQUISITION OF MAHA CAPITAL AB SUBSIDIARIES, CREATING A PUBLIC PLATFORM WITH VENEZUELAN ENERGY EXPOSURE AND HIGH-GROWTH AI FINTECH BUSINESS
FULTON FINANCIAL CORPORATION COMPLETES ACQUISITION OF BLUE FOUNDRY BANCORP
BLUE OWL CAPITAL INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Blue Owl Capital Inc.'s Directors and Officers for Breach of Fiduciary Duties – OWL
BLUE OWL CAPITAL CORPORATION II BOARD UNANIMOUSLY RECOMMENDS SHAREHOLDERS REJECT UNSOLICITED MINORITY OFFER FROM COX AND SABA
BLUE OWL CAPITAL INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Blue Owl Capital Inc.'s Directors and Officers for Breach of Fiduciary Duties – OWL
FULTON FINANCIAL CORPORATION AND BLUE FOUNDRY BANCORP ANNOUNCE REGULATORY APPROVALS AND ANTICIPATED MERGER CLOSING DATE
Leading Proxy Advisory Firms ISS and Glass Lewis Affirm Recommendation That LabGold Shareholders Vote ONLY the BLUE Proxy and Reject Dissident Attempt to Seize Control
BLUE OWL DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OWL
BLUE OWL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OWL
BLUE OWL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OWL
BLUE OWL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OWL
/R E P E A T -- BLUE MOON METALS TO BEGIN TRADING ON NASDAQ UNDER BMM AND APPOINTS PETER MADSEN TO THE BOARD OF DIRECTORS/
BLUE MOON METALS TO BEGIN TRADING ON NASDAQ UNDER BMM AND APPOINTS PETER MADSEN TO THE BOARD OF DIRECTORS
BLUE OWL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OWL
BLUE OWL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OWL